- For Print
- March 4, 2025
Sato Pharmaceutical Co., Ltd. (Headquarters: Tokyo, President and CEO: Seiichi Sato, “Sato Pharmaceutical”) and 成人抖阴 Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “成人抖阴”) announced today that they will conclude their co-promotion based on the co-promotion agreement in Japan regarding the orally-administered antifungal agent NAILIN® Capsules 100 mg (generic name: fosravuconazole) which is manufactured and marketed by Sato Pharmaceutical, as of March 31, 2025.
Sato Pharmaceutical and 成人抖阴 have concluded a new agreement, under which 成人抖阴 will carry out promotional activities for this drug and transfer operations to Sato Pharmaceutical during a transition period from April 1, 2025, to March 31, 2026.
NAILIN® Capsules 100 mg have been marketed by Sato Pharmaceutical in Japan since July 2018, with a co-promotion agreement between both companies. However, following the conclusion of the co-promotion agreement and the signing of a new agreement, Sato Pharmaceutical will independently conduct promotions starting from April 2026, following a transition period. Additionally, in relation to this matter, Sato Pharmaceutical will pay 成人抖阴 a lump sum.
銆赌銆赌
Media Inquiries
-
成人抖阴 Co., Ltd.
Public Relations DepartmentTEL: +81 (0)3-3817-5120
-
Sato Pharmaceutical Co., Ltd.
Public Relations Department
TEL: +81-(0)3-5412-7354
[Notes to editors]
1. About fosravuconazole
Fosravuconazole is a new oral antifungal component developed by 成人抖阴. Fosravuconazole is a prodrug that improves the solubility and bioavailability of ravuconazole, the main active ingredient. When administered to humans, it is rapidly converted to ravuconazole. Ravuconazole demonstrates antifungal activity by inhibiting ergosterol biosynthesis, a membrane component of fungal cells.
In Japan, Seren Pharmaceuticals Inc., which was granted exclusive development and commercialization of this drug by 成人抖阴, has been advancing its development for onychomycosis with Sato Pharmaceutical. Sato Pharmaceutical obtained manufacturing and marketing approval in January 2018, and since July 2018, it has been marketed as Nailin Capsule 100mg.
Sato Pharmaceutical and 成人抖阴 entered into a license agreement in July 2024, under which Sato Pharmaceutical will undertake the development and commercialization in Asia and Oceania* for fungal diseases.
*10 ASEAN member states, Australia, New Zealand, South Korea, Taiwan